Psychopharmacology Books

Book SynopsisTHE DEFINITIVE GUIDE TO CANNABIS AND YOUR HEALTHUnderpinned by his two-year research trial in partnership with the Royal College of Psychiatrists, involving up to 20,000 patients, which will create Europe's largest body of evidence on the plant's medicinal qualities - Professor David Nutt and his team of scientists will break the mould on the way we use Cannabis for our health in the future.In David's first ground-breaking book on the subject, he will cover its impact of all areas of the body and the brain and its effective use for treatment of illness from chronic pain, epilepsy, multiple sclerosis and PTSD, to anxiety and depression. This is the essential knowledge that cuts through the noise and give us evidence-based information that will change people's lives.

Read more less

Book Synopsis

Read more less

Book SynopsisWe are on the cusp of a major revolution in psychiatric medicine and neuroscience. After fifty years of prohibition, criminalisation and fear, science is finally showing us that psychedelics are not dangerous or harmful. Instead, when used according to tested, safe and ethical guidelines, they are our most powerful newest treatment of mental health conditions, from depression, PTSD, and OCD to disordered eating and even addiction and chronic pain.Professor David Nutt, one of the world's leading Neuropsychopharmacologists, has spent 15 years researching this field and it is his most significant body of work to date. In 2018, he co-founded the first academic psychedelic research centre - underpinned by his mission to provide evidence-based information for people everywhere. It revived interest in the understanding and use of this drug in its many forms, including MDMA, ayahuasca, magic mushrooms, LSD and ketamine. The results of this have been nothing short of ground-breaking for the future categorisation of drugs, but also for what we now know about brain mechanisms and our consciousness.At a time where there is an enormous amount of noise around the benefits of psychedelics, this book contains the knowledge you need to know about a drug that is about to go mainstream, free from the hot air, direct from the expert.Are you ready to change your mind?

Read more less

Book SynopsisMost twentysomethings don't have disorders that need to be treated; they have problems that need to be solved.

Read more less

Book SynopsisReal-world and clinical trial data support that clozapine is the only effective antipsychotic for treatment resistant schizophrenia and other severe mental illnesses. Clozapine also reduces rates of suicidality, psychiatric hospitalization and all-cause mortality. However, clozapine is underutilized for two reasons: misunderstandings of its efficacy benefits and misapprehension of, limited knowledge or misinformation about the management of treatment related risks and adverse effects. In response to worldwide efforts to promote clozapine use, this user-friendly Handbook provides clinicians with evidence-based approaches for patient management, as well as logical approaches to the management of clinical situations and adverse effects. It outlines clearly the rationale for specific management decisions and prioritises the options based on this logic. This Handbook is designed for use by clinicians worldwide and is essential reading for all mental health care professionals.Table of ContentsPreface; 1. Initiating Clozapine; 2. Understanding hematologic monitoring and benign ethnic neutropenia; 3. Binding profile, metabolism, kinetics, drug interactions and use of plasma levels; 4. Managing constipation; 5. Managing sialorrhea; 6. Managing sedation, orthostasis and tachycardia; 7. Managing metabolic adverse effects; 8. Managing seizure risk and stuttering; 9. Fever, myocarditis, interstitial nephritis, DRESS, serositis and cardiomyopathy; 10. Eosinophilia, leukocytosis, thrombocytopenia, thrombocytosis, anemia, hepatic function abnormalities; 11. Managing enuresis and incontinence, priapism, venous thromboembolism, neuroleptic malignant syndrome, tardive dyskinesia and obsessive compulsive disorder; 12. The efficacy story: treatment resistant schizophrenia, psychogenic polydipsia, treatment intolerant schizophrenia, suicidality, violence, mania and Parkinson's disease psychosis; 13. Addressing clozapine positive symptom nonresponse in schizophrenia spectrum patients; 14. Discontinuing clozapine and management of cholinergic rebound; 15. Special topics: child and adolescent patients, elderly patients, patients with intellectual disability, pregnancy and risk for major congenital malformation, lactation, overdose, postmortem redistribution; Index.

Read more less

Book SynopsisThis spin-off from Stephen M. Stahl''s new, completely revised, and fully updated sixth edition of the Prescriber''s Guide covers the most important drugs in use today for treating patients suffering from psychotic illness. Now established as the indispensable formulary in psychopharmacology, easy to navigate and easy to use, the Prescriber''s Guide combines evidence-based information with clinically informed guidance to support clinicians in making the most effective prescribing decisions for the good of their patients. Incorporating information on the newest indications, new formulations, new recommendations and new safety data, this edition continues to provide the essential practical support required by anyone prescribing in the field of mental health.Table of ContentsIntroduction; List of icons; 1. Amisulpride; 2. Aripiprazole; 3. Asenapine; 4. Blonanserin; 5. Brexpiprazole; 6. Cariprazine; 7. Chlorpromazine; 8. Clozapine; 9. Cyamemazine; 10. Flupenthixol; 11. Fluphenazine; 12. Haloperidol; 13. Iloperidone; 14. Loxapine; 15. Lurasidone; 16. Mesoridazine; 17. Molindone; 18. Olanzapine; 19. Paliperidone; 20. Perospirone; 21. Perphenazine; 22. Pimavanserin; 23. Pimozide; 24. Pipothiazine; 25. Quetiapine; 26. Risperidone; 27. Sertindole; 28. Sulpiride; 29. Thioridazine; 30. Thiothixene; 31. Trifluoperazine; 32. Ziprasidone; 33. Zotepine; 34. Zuclopenthixol; Index by drug name; Index by use; Abbreviations.

Read more less

Trade Review"the definitive psychology text on willpower" --John Cloud, Time Magazine June 12 2006Table of ContentsForeword About the Editors 1: Self-Regulation: An Introductory Overview Part I: General Theories and Models of Self-Regulation 2: Attaining Self-Regulation: A Social Cognitive Perspective I INTRODUCTION II THE STRUCTURE OF SELF-REGULATORY SYSTEMS III SOCIAL AND ENVIRONMENTAL INFLUENCES ON SELF-REGULATION IV DYSFUNCTIONS IN SELF-REGULATION V DEVELOPMENT OF SELF-REGULATORY SKILL VI FUTURE RESEARCH DIRECTIONS VII A CONCLUDING COMMENT ACKNOWLEDGMENT 3: On the Structure of Behavioral Self-Regulation I BEHAVIOR IS GOAL DIRECTED AND FEEDBACK CONTROLLED II HIERARCHICALITY AMONG GOALS III FEEDBACK CONTROL AND CREATION OF AFFECT IV CONFIDENCE AND DOUBT, PERSISTENCE AND GIVING UP V DYNAMIC SYSTEMS AND HUMAN BEHAVIOR VI CATASTROPHE THEORY VII CONCLUDING COMMENT ACKNOWLEDGMENT 4: Aspects of Goal Networks: Implications for Self-Regulation I A STRUCTURAL ANALYSIS OF GOAL NETWORKS II SELF-REGULATORY CONSEQUENCES OF GOAL NETWORK STRUCTURE III INDIVIDUAL DIFFERENCES IN THE STRUCTURE OF GOALS AND MEANS IV COMPARISON TO OTHER PERSPECTIVES ON GOAL NETWORKS V FUTURE DIRECTIONS: INTERPERSONAL GOALS VI CONCLUSION 5: A Functional-Design Approach to Motivation and Self-Regulation: The Dynamics of Personality Systems Interactions I INTRODUCTION II DYNAMIC CONCEPTS IN CLASSICAL THEORIES OF MOTIVATION III ARISTOTLE’S DYNAMIC CONCEPTS IV PERSONALITY SYSTEMS INTERACTION THEORY V BACK TO THE FUTURE: FROM CONTENTS TO MECHANISMS VI CONCLUSION ACKNOWLEDGMENT 6: Personality, Self-Regulation, and Adaptation: A Cognitive–Social Framework I FRAMEWORKS FOR PERSONALITY AND SELF-REGULATION RESEARCH II SELF-REGULATION, TRAITS, AND COGNITIVE STRESS PROCESSES III PERSONALITY AND SELF-REGULATION OF REACTIONS TO LIFE STRESS IV PERSONALITY AND SELF-REGULATION IN PERFORMANCE ENVIRONMENTS V AGGRESSIVE BEHAVIOR VI CONCLUSIONS 7: Organization and Development of Self-Understanding and Self-Regulation: Toward a General Theory I INTRODUCTION II THE ARCHITECTURE OF SELF-AWARE AND SELF-REGULATED SYSTEMS III DEVELOPMENT OF SELF-UNDERSTANDING AND SELF-REGULATION IV EXPLAINING THE DEVELOPMENT OF SELF-UNDERSTANDING AND SELF-REGULATION V CONCLUSIONS 8: The Role of Intention in Self-Regulation: Toward Intentional Systemic Mindfulness I SYSTEMS THEORY, SELF-REGULATION, AND MINDFULNESS II SELF-REGULATION III SELF-REGULATION TECHNIQUES AND POTENTIAL LIMITATIONS IV PSYCHOPHYSIOLOGICAL RESEARCH ON SELF-REGULATION — PHYSIOLOGY AND ENERGY V ELABORATION OF AN EXPANDED SELF-REGULATION MODEL: INTENTION VI INTENTION VII INTENTIONAL SYSTEMIC MINDFULNESS: MINDFULNESS QUALITIES AND SYSTEMIC PERSPECTIVES VIII APPLICATIONS OF INTENTIONAL SYSTEMIC MINDFULNESS TO SELF-REGULATION TECHNIQUES IX CONNECTEDNESS AND INTERCONNECTEDNESS X GENERAL PRINCIPLES OF INTENTIONAL SYSTEMIC MINDFULNESS INTERVENTIONS XI FACILITATING INTENTION SYSTEMIC MINDFULNESS XII DIRECTIONS FOR FUTURE RESEARCH XIII IMPLICATIONS FOR HEALTH AND MEDICINE XIV SUMMARY ACKNOWLEDGMENTS 9: Communal Aspects of Self-Regulation I INTRODUCTION II COPING AS SELF-REGULATION III SUMMARY AND CONCLUSION ACKNOWLEDGMENT Part II: Domain-Specific Models and Research on Self-Regulation 10: Self-Regulation in Organizational Settings: A Tale of two Paradigms I INTRODUCTION II DEFINITIONS III TWO PARADIGMS IV THE PARADIGMS IN INDUSTRIAL– ORGANIZATIONAL PSYCHOLOGICAL THEORIES OF SELF-REGULATION V MERGING THE PARADIGMS VI CONCLUSION 11: Self-Regulation and Health Behavior: The Health Behavior Goal Model I INTRODUCTION II CURRENT HEALTH BEHAVIOR MODELS AND SELF-REGULATION III SELF-REGULATION AND THE PERSONAL GOAL STRUCTURE IV GOAL ALIGNMENT, GOAL CONFLICT, AND GOAL BALANCE V GOAL SETTING AND GOAL ORIENTATION VI GOALS, BELIEFS, AND EMOTIONS VII THE SELF-REGULATION PROCESS VIII THE HEALTH BEHAVIOR GOAL MODEL IX CONCLUSION AND DIRECTIONS FOR FUTURE RESEARCH ACKNOWLEDGMENT 12: Regulation, Self-Regulation, and Construction of the Self in the Maintenance of Physical Health I THE SELF-REGULATION THEME II PROBLEM SOLVING, SELF-REGULATION, AND REGULATION OF THE SELF III MODELING PROBLEM SOLVING, SELF-REGULATION, AND SELF-CONSTRUCTION IV ILLNESS COGNITION AND CONTROL THEORY V COPING PROCEDURES: GENERALIZED FACTORS VERSUS IF-THEN RULES THAT INTEGRATE REPRESENTATIONS, PROCEDURES, AND APPRAISALS VI THE SELF SYSTEM VII SUMMARY AND CONCLUDING COMMENTS ACKNOWLEDGMENT 13: Self-Regulated Learning: Finding a Balance Between Learning Goals and Ego-Protective Goals I INTRODUCTION II WHAT TURNS A POTENTIAL LEARNING OPPORTUNITY INTO A SITUATION THAT THE STUDENT IDENTIFIES AS SUCH? III SELF-REGULATED LEARNING ORIGINATES IN THE IDENTIFICATION, INTERPRETATION, AND APPRAISAL OF AN OPPORTUNITY TO LEARN IV GOAL SETTING: AN ESSENTIAL ASPECT OF SELF-REGULATED LEARNING V SELF-REGULATED LEARNING IMPLIES GOAL STRIVING VI CONCLUSIONS AND FUTURE DIRECTIONS 14: The Role of Goal Orientation in Self-Regulated Learning I A GENERAL FRAMEWORK FOR SELF-REGULATED LEARNING II GOAL ORIENTATION AND SELF-REGULATED LEARNING III CONCLUSIONS AND FUTURE DIRECTIONS FOR THEORY AND RESEARCH ACKNOWLEDGMENTS 15: Motivation and Action in Self-Regulated Learning I INTRODUCTION AND CONCEPTUAL FRAMEWORK II AN ACTION MODEL FOR THE PREDICTION OF LEARNING MOTIVATION III MOTIVATION, LEARNING, AND PERFORMANCE IV TWO AIMS FOR FURTHER RESEARCH ACKNOWLEDGMENTS 16: Measuring Self-Regulated Learning I MEASURING INTERVENES IN AN ENVIRONMENT II MEASUREMENTS OF SELF-REGULATED LEARNING REFLECT A MODEL OF SELF-REGULATED LEARNING III PROTOCOLS FOR MEASURING SELF-REGULATED LEARNING IV ISSUES IN MEASURING SELF-REGULATED LEARNING V CONCLUSIONS AND FUTURE DIRECTIONS ACKNOWLEDGMENT Part III: Interventions and Applications of Self-Regulation Theory and Research 17: Self-Regulation and Distress in Clinical Psychology I INTRODUCTION II SELF-REGULATION AND ADDICTIVE BEHAVIORS III SELF-REGULATION AND HEALTH IV SELF-REGULATION AND SOCIAL ANXIETY V SELF-REGULATION AND DEPRESSION VI SELF-REGULATION AND THERAPY VII SUMMARY AND CONCLUSIONS ACKNOWLEDGMENT 18: Self-Management of Chronic Illness I INTRODUCTION II CHARACTERISTICS OF CHRONIC ILLNESS III TREATMENT OF CHRONIC ILLNESS IV SELF-MANAGEMENT: SETTING THE STAGE V PROCESSES OF SELF-MANAGEMENT VI DISCUSSION VII FUTURE DIRECTIONS AND CONCLUSIONS 19: Self-Regulation and Academic Learning: Self-Efficacy Enhancing Interventions I INTRODUCTION II THEORETICAL FRAMEWORK III RESEARCH EVIDENCE IV INTERVENTIONS TO ENHANCE SELF-EFFICACY AND SELF-REGULATION V FUTURE RESEARCH ON SELF-REGULATION VI CONCLUSION 20: Teacher Innovations in Self-Regulated Learning I INTRODUCTION II OVERVIEW III STRATEGY INSTRUCTION RESEARCH IN THE CONTENT AREAS IV STRATEGY INSTRUCTION THROUGH COLLABORATIVE INNOVATION V DEVELOPING A MODEL FOR TEACHING SELF-REGULATED LEARNING THROUGH STORY VI COLLABORATIVE RESEARCH: FUTURE POSSIBILITIES VII SUMMARY 21: Self-Regulation: A Characteristic and a Goal of Mathematics Education I INTRODUCTION II LEARNING MATHEMATICS FROM INSTRUCTION: OUTLINE OF A THEORETICAL FRAMEWORK III STUDENTS’ FLAWS IN SELF-REGULATORY SKILLS AND BELIEFS IV FOSTERING STUDENTS’ SELF-REGULATION IN POWERFUL MATHEMATICS LEARNING ENVIRONMENTS 22: Self-Regulation Interventions with a Focus on Learning Strategies I HISTORICAL OVERVIEW II LEARNING STRATEGIES CAN BE MODIFIED OR LEARNED III THE NATURE OF STRATEGIES AND STRATEGY INSTRUCTION IV TYPES OF LEARNING STRATEGIES AND THEIR RELATIONSHIP TO OTHER STRATEGIC LEARNING COMPONENTS V MODEL OF STRATEGIC LEARNING VI TYPES OF STRATEGY INSTRUCTION AND THEIR EFFECTIVENESS VII IMPORTANT COMPONENTS OF ADJUNCT COURSES VIII THE NATURE AND IMPACT OF A COURSE IN STRATEGIC LEARNING AT THE UNIVERSITY OF TEXAS IX FUTURE DIRECTIONS FOR LEARNING STRATEGIES RESEARCH 23: Self-Regulation: Directions and Challenges for Future Research I DEVELOPING A TRACTABLE CONCEPTUAL FOUNDATION AND CONSISTENT NOMENCLATURE OF SELF-REGULATION CONSTRUCTS II CLARIFYING SELF-REGULATION STRUCTURE AND PROCESSES III MAPPING OUT THE NOMOLOGICAL NETWORK IV CONSTRUCTION OF MORE REFINED MODELS V REFINING MEASUREMENT OF SELF-REGULATION CONSTRUCTS VI IMPROVING RESEARCH METHODOLOGY VII EXPLORING INTERACTIONS BETWEEN ENVIRONMENT AND SELF-REGULATION VIII ACQUISITION AND TRANSMISSION OF SELF-REGULATORY SKILLS IX EXAMINING DEVELOPMENTAL DIFFERENCES IN SELF-REGULATORY SKILLS X EXAMINING INDIVIDUAL DIFFERENCES IN SELF-REGULATORY SKILLS XI APPLICATIONS XII TRAINING AND PROMOTION OF SELF-REGULATORY CONCEPTS Index

Read more less

Book SynopsisCutting-edge explorations and discussions of DMT experiences and plant sentience from leading luminaries in the field of psychedelic research. Encounters with apparently sentient beings are reported by half of all first time users of the naturally occurring psychedelic DMT, yet the question of DMT beings and plant sentience, interspecies communication, discarnate consciousness, and perhaps even dialoguing with the divine has never been systematically explored. Offering cutting-edge insights into this visionary domain, this book distills the potent exchange of ideas that occurred at Tyringham Hall, including presentations and discussions on DMT entities, the pineal gland, the possibility of DMT as a chemical messenger from an extraterrestrial civilization, the Amazonian shamanic perspective on Invisible Entities, morphic resonance, and the science behind hallucinations. Contributors to the talks and discussions include many leading thinkers in this field, including Rupert Sheldrake, Rick Strassman, Dennis McKenna, Graham Hancock, Jeremy Narby, Erik Davis, Ede Frecska, Luis Eduardo Luna, Peter Meyer, Jill Purce, David Luke, and Cosmo Feilding Mellen, among many others. Trade Review“DMT Dialogues is a courageous attempt in the best tradition of the scientific process to wrestle with the meaning of anomalous DMT experiences, reported by a substantial number of people, involving the sense of being in touch with alien intelligences. Like all great mysteries, there is no single interpretation that everybody who participated in the DMT Dialogues arrived at by consensus. Reading DMT Dialogues will not bring you certainty but rather will bring you in direct contact with profound minds struggling to plumb the depths of consciousness.” * Rick Doblin, Ph.D., executive director of the Multidisciplinary Association for Psychedelic Studies *“These dialogues are a promising and positive attempt to create a pivotal shift in consciousness. Centered on the farthest reaches of human experience, they offer fresh perspectives and open new doors. They merit being read--and read over and over again, in our own as well as in humankind’s most general interest.” * Ervin Laszlo,The Intelligence of the Cosmos *“DMT Dialogues represents an important step in the scholarly conversation about the DMT world and the entities which inhabit it. By presenting insightful contributions from experts in psychology, anthropology, religious studies, and neuroscience, as well as the interdisciplinary discussions that followed, the editors have provided the theoretical tools needed to start interpreting and understanding the DMT experience. As part of the Beckley/Imperial Research Programme we are currently investigating how DMT has its effect in the brain in a pioneering study using EEG and fMRI.” * Amanda Feilding, founder of The Beckley Foundation *“DMT is famous in the world of psychedelic research for inducing experiences that are short, a matter of minutes, but with effects that are profoundly dazzling and lead to lengthy essays that try to explicate the puzzle. It clearly affects the language centers of the brain! It has led to the recognition of DMT entities, which may or may not be a new class of weird beings, neither animal nor plant, molecular nor metaphysical. This book is a fascinating series of explorations of the paradigm-busting and mind-blowing experiences triggered by this substance. Just reading about them is mind-blowing!” * Ralph Metzner, Ph.D., author of Searching for the Philosophers’ Stone *“Preserved in the pages of this book are some of the most extraordinary presentations I have ever had the pleasure to read. It was my privilege to attend the 2017 Tyringham Initiative DMT Symposium and to learn firsthand from the assembled scientists and scholars about their research into DMT. This substance opens doors into a hidden world, and to listen to--and read--these presentations is to discover that powerful advances are being made into understanding its meaning and potential.” * Whitley Strieber, author of Communion and The Super Natural *“DMT Dialogues showcases the incredible, groundbreaking work of the Tyringham Initiative, which convenes cutting-edge thinkers and scientists exploring the edge-realms of the psyche, with the intention of furthering humanity’s understanding of what lies beyond the edge of the known.” * Daniel Pinchbeck, author of Breaking Open the Head *“DMT has a rich cultural history, a radically vibrant contemporary social context, complex biological mechanisms, theological and philosophical implications, and far-reaching implications for the science of consciousness. In DMT Dialogues, David Luke and Rory Spowers have curated an accessible anthology that sparks off in many of these directions and then kindles them together into a Promethean fire for our times. Where do we go as a species with all this rising knowledge of the extraordinary farther reaches of the mind? Only time will tell, and I’m sure this book will help us find the way.” * Oliver Robinson, Ph.D., author of Paths between Head and Heart *Table of ContentsForeword About the Entheogenic Plant Sentience Symposium Rory Spowers Preface Objectives of the Symposium David Luke Acknowledgments DAY ONE The Origins, Evolution, and Esoteric Culture of DMT Introduction Exploring Entheogenic Entity Encounters Anton Bilton Chapter 1 The Pineal Enigma: The Dazzling Life and Times of the “Spirit Gland” Graham St. John DISCUSSION Chapter 2 Is DMT a Chemical Messenger from an Extraterrestrial Civilization? Dennis McKenna DISCUSSION DAY TWO Frameworks for Thinking about DMT Chapter 3 Amazonian Perspectives on Invisible Entities Jeremy Narby DISCUSSION Chapter 4 Concerning the Nature of the DMT Entities and Their Relation to Us Peter Meyer DISCUSSION Chapter 5 How to Think about Weird Beings Erik Davis DISCUSSION Chapter 6 Why May DMT Occasion Veridical Hallucinations and Informative Experiences? Ede Frecska DISCUSSION DAY THREE Exploring the Whole of Reality Chapter 7 The Neurobiology of Conscious Interaction with Alternate Realities and Their Inhabitants Andrew Gallimore DISCUSSION Chapter 8 Morphic Resonance, Psychedelic Experience, and Collective Memory Rupert Sheldrake DISCUSSION Chapter 9 Psychedelics, Entities, Dark Matter, and Parallel Dimensions Graham Hancock DISCUSSION Chapter 10 The Nature of DMT Beings: Perspectives and Prospects Rick Strassman DAY FOUR Summary and Departure Chapter11 What We Think We Know about DMT Entities David Luke Afterword What Next? Rory Spowers Speaker Citations Speaker Biographies Discussant Biographies Editor and Symposium Curator Biographies Index

Read more less

Book SynopsisTrade ReviewAltered States genuinely moves forward in laying a path for new, insightful, and valuable information on the American Buddhism that is developing in our global society. D. E. Osto's groundbreaking research will be appreciated by scholars, and their accessible style will be enjoyed by nonacademic readers. -- Charles Prebish, author of Luminous Passage: The Practice and Study of Buddhism in AmericaAltered States deftly guides us through the neglected territory of psychedelic Buddhism. This is a fascinating story, full of vivid characters and supported by solid research. Still, I believe it makes a greater contribution by situating these practices and persons within the larger contexts of tantra, of American religion, and of cutting-edge neuropsychology and consciousness studies. The result is—to use le mot juste—mind blowing. -- Franz Metcalf, author of What Would Buddha Do?: 101 Answers to Life's Daily Dilemmas"[Altered States] mixes statistics and surveys, historical overview, personal experience, and ethnographic texture to uncover the intertwining history of two fast-growing movements in American spirituality.... This overview will appeal to anyone interested in Buddhism, psychedelic possibilities, and understanding how both are forging a controversial new American religious experience. * Publishers Weekly *Osto’s book is exceptional in its ability to focus the conversation about entheogens within religious perspectives. . . . They also point to more complex questions regarding the nature of subjectivity, experience, and scientific study. * Religious Theory *Of interest to anyone who wants to explore the intersection between traditional religion and altered states of consciousness, be they induced by psychedelics or any other means. * OPEN *Provocative.... The book is worth buying, reading, and quoting. * PsycCritiques *Table of ContentsPrefaceAcknowledgmentsIntroduction1. Buddhism and the Psychedelic Connection2. The Psychedelic Revolution3. The Buddhist Revolution4. Opening the Door: Psychedelics as a Gateway to Buddhist Practice5. Closing the Door: The Fifth Precept and Graduating from Psychedelics6. Keeping the Door Open: Psychedelics as an Adjunct to Buddhist Practice7. Are Psychedelics "the True Dharma"?: Debates, Presuppositions, and Philosophical IssuesConclusionsPostscriptNotesBibliographyIndex

Read more less

Book SynopsisSuccinct, authoritative, and affordable, Kaplan & Sadock’s Concise Textbook of Psychiatry, 5th Edition, provides must-know information in clinical psychiatry from the names you trust. From cover to cover, it contains the most relevant clinical material from the bestselling Kaplan and Sadock’s Synopsis of Psychiatry, 12th Edition, including the foundational chapters on assessment, the disorder specific chapters, and all of the treatment-specific chapters among other essential topics such as emergency psychiatry, ethics, and palliative/end-of-life care. New editors Robert Boland and Marcia L. Verduin, along with consulting editor Pedro Ruiz, have updated all content with a focus on reformatting and summarizing for faster access to key information. Provides concise but thorough coverage of the entire field of clinical psychiatry, including biologic, psychologic, and sociologic factors in health and disease. Offers step-by-step guidance on the clinical examination, the psychiatric report, medical assessment of the psychiatric patient, laboratory tests, and signs and symptoms, as well as all psychiatric and substance-related disorders, with special chapters on children, adolescents, and the elderly. Presents the most current treatment methods including descriptions of all modern psychotherapeutic techniques. Contains real-world case histories throughout and features a unique glossary of psychiatric signs and symptoms. Includes thorough updates and revisions throughout, all consistent with the DSM-5. Presents a comprehensive overview of the clinical aspects of psychiatry for clinicians, residents, students, and all others who provide mental health care. , Enrich Your eBook Reading Experience Read directly on your preferred device(s), such as computer, tablet, or smartphone. Easily convert to audiobook, powering your content with natural language text-to-speech. ,

Read more less

Book SynopsisNow in vibrant full color, Kaplan and Sadock’s Pocket Handbook of Psychiatric Drug Treatment, 8th Edition, remains your reference of choice for easy-to-find information on the full spectrum of psychiatric drug therapies. Written by Dr. Samoon Ahmad, this trusted resource provides a wealth of data for each drug, presenting information in a clear, concise manner for quick, efficient retrieval. This edition brings you fully up to date in the field, with new information on cannabis, psychedelics, psychotropic medicines and medical comorbidities, genetics and pharmacogenomics testing, and more. Includes new chapters on cannabis; psychedelics such as psilocybin, MDMA, and ketamine; and genetics and the role of pharmacogenomics testing, brain stimulation, and other novel technologies in psychiatry Includes many new FDA-approved drugs, as well as updated information about drug selection and use that reflects both research data and clinical experience Addresses the complex relationship between the use of psychotropic medicines and medical comorbidities, including metabolic complications, with emphasis on recognition, investigations, treatment, and management Features a new, full-color format with color icons that highlight side effects, notable benefits, and other important indications for each drug Provides a wealth of data for each drug: chemical name; preparation and dosages; pharmacologic actions; indications for use and clinical applications; use in children, elderly persons, and pregnant and nursing women; side effects and adverse and allergic reactions; and drug-drug interactions Ideal for psychiatrists and other physicians, as well as psychiatric residents, medical students, clinical psychologists, psychiatric nurses, and other professionals who provide care for patients with mental illness Enrich Your eBook Reading Experience Read directly on your preferred device(s), such as computer, tablet, or smartphone. Easily convert to audiobook, powering your content with natural language text-to-speech.

Read more less

THE DEFINITIVE GUIDE TO CANNABIS AND YOUR HEALTHUnderpinned by his two-year research trial in partnership with the Royal College of Psychiatrists, involving up to 20,000 patients, which will create Europe's largest body of evidence on the plant's medicinal qualities - Professor David Nutt and his team of scientists will break the mould on the way we use Cannabis for our health in the future. In David's first ground-breaking book on the subject, he will cover its impact of all areas of the body and the brain and its effective use for treatment of illness from chronic pain, epilepsy, multiple sclerosis and PTSD, to anxiety and depression. This is the essential knowledge that cuts through the noise and give us evidence-based information that will change people's lives.

Read more less

Book SynopsisOur twenties can be challenging. Today, so many twentysomethings are struggling, especially with anxiety and depression, and yet we're not sure what to think or do about it. In The Twentysomething Treatment psychologist Dr. Meg Jay explores why and unveils a ground-breaking approach that prioritizes skills over pills.As a seasoned clinical psychologist specialising in the unique challenges of this pivotal decade, Dr. Jay dismantles the myth that twentysomethings are fragile beings and explains why medication is sometimes, but not always, the best medicine.Within the transformative pages of this book, Dr. Jay provides practical solutions for a range of problems as she expertly guides readers through finding purpose and embracing uncertainty without unravelling. She offers actionable advice on navigating the intricacies of work, love, sex, friendship, confidence, health and happiness.The Twentysomething Treatment is not just a book; it''s a lifeline for a generation grappling with a ment

Read more less

Book Synopsis

Read more less

Book SynopsisFinancial Times Business Top Title March 2022How could a large collection of small companies, most with fewer than 50 employees, rise to compete with Big Pharma, one of the world''s most breathtakingly expensive and highly regulated industries?Beginning in the 1970s, several scientific breakthroughs promised to transform the creation of new medicines. As investors sought to capitalize on these Nobel Prize-winning discoveries, the biotech industry grew to thousands of small companies around the world. Each sought to emulate what the major pharmaceutical companies had been doing for a century or more, but without the advantages of scale, scope, experience, and massive resources. Biotech companies have met the challenge by creating nearly 40% more of the most important treatments for previously unmet medical needs. Moreover, they have done so with much lower overall costs. From Breakthrough to Blockbuster: The Business of Biotechnology focuses on both the companies themselves and the broaTrade ReviewWritten with authority * Financial Times *A fascinating guide to the complex business of biotechnology, with deep insights into the key factors, players, interactions and behaviors that have shaped the success of this industry. Suitable as a primer for those with no knowledge of the field, or as a refresher for the cognoscenti. Trigger warning: contains material that may distress pharma management * Sir Gregory Winter FRS, Trinity College, Cambridge University, recipient of 2018 Nobel Prize in Chemistry *A must read for all biotechnology leaders, this is a state-of-the-art analysis of the industry from two of its most successful entrepreneurs and a top business school professor, bringing rigor and actionable insight. * Dr Richard Mason, CEO of Apollo Therapeutics and former head of Johnson & Johnson's London Innovation Center *How is it possible that a few thousand small companies, many of them short-lived, can out-compete the mighty pharma majors at their own game? Understanding this puzzle is of fundamental importance for industry leaders and policy makers alike. This marvelous insider analysis is a must-read. * Stefan Scholtes, Dennis Gillings Professor of Health Management, Cambridge University Centre for Health Leadership & Enterprise *A remarkable synthesis and analysis of the Biotech industry that is a must-read for those trying to develop new life-saving medicines. * Margaret A. Liu, M.D., DSchc, MDhc, FISV, CEO of Pax Therapeutics, and board member, Ipsen, S.A. *Anyone who wants to understand how to leverage ecosystems for innovation in the face of uncertainty must read this rigorous analysis of how biotech companies, investors, government and big pharma have worked together to achieve some of the biggest scientific and commercial breakthroughs of the last century. * Arnoud De Meyer, Professor Emeritus and former President, Singapore Management University *A must read for everybody interested in the medical biotech industry, practically relevant and theoretically sound. * Jürgen Mihm, , Professor of Technology and Operations Management at INSEAD *An outstanding overview of the science and the business of innovative drugs. Students, researchers and policy makers will be immensely benefited from this book. * Mahmud Hassan, Ph.D, Professor and Director, Pharmaceutical Management Program, Rutgers Business School *Table of ContentsList of Figures and Tables Preface Chapter 1: Following the Map of the Genome Chapter 2: The Molecules Chapter 3: The Costly Drug Development Process Chapter 4: The Companies Chapter 5: Biotech-Pharma Alliances Chapter 6: The Biotech Entrepreneur Chapter 7: The Biotech Industry Track Record Chapter 8: The Future of the Biotech Industry Appendix 1 Appendix 2 Bibliography Index About the Authors

Read more less

Book SynopsisIntroduction to Neuropsychopharmacology expands on the molecular and cellular foundations of the classic Biochemical Basis of Neuropharmacology, Eighth Edition (Cooper, Bloom, and Roth) by now including the behavioral methods used to study psychoactive drugs in experimental animals and in humans. Authored by four founders of modern neuroscience, this concise and comprehensive text covers the current series of medications used to treat diseases of the brain and nervous system--both psychiatric and neurologic--as well as legal and illegal recreational drugs and the neuroscientific information that explains how these medications act on the brain from the molecular to the clinical level. The text ranges from drugs that affect the mood and behavior to hypnotics, narcotics, anticonvulsants, and analgesics.Trade ReviewThis informative and readable new introductory textbook should be required reading for any medical student, graduate student, or physician interested in understanding neuroscience...an outstanding learning tool. * Doody's Notes *Table of ContentsCONTENTS; CONTRIBUTORS

Read more less

Book SynopsisIn his latest book, science writer and medicinal chemist Jie Jack Li guides readers through the history of viruses, vaccines, and antiviral drugs. Li chronicles the discovery and treatment of HIV/AIDS, hepatitis, influenza, and coronaviruses. Throughout, Li focuses on how viruses have shaped human history and on the individuals who developed treatments.Table of ContentsPreface Chapter 1. Virus Shaping History and Discovery of Virus 1.1 Virus shaping history 1.1.1 Tulipomania: bubbles of bulbs 1.1.2 The fall of old Mexico and Peru 1.1.3 Succession of thrones 1.1.4 The Louisiana Purchase 1.2 Discovery of virus 1.2.1 The gem theory 1.2.2 Discovery of virus 1.2.3 Cancer-causing viruses 1.2.4 Discovery of retrovirus Chapter 2. HIV/AIDS Drugs, Transforming a Death Sentence to a Chronic Disease 2.1 Discovery of the virus 2.1.1 A death sentence 2.1.2 Discovery of HIV and the great scientific controversy 2.1.3 The Nobel Prize 2.2 The first ray of hope 2.2.1 Nucleoside antiviral drugs 2.2.2 Non-nucleoside reverse transcriptase inhibitors 2.3 HIV protease inhibitors 2.3.1 HIV protease 2.3.2 First-generation HIV protease inhibitors 2.3.3 Second-generation HIV protease inhibitors 2.4 HIV integrase inhibitors 2.5 HIV Entry Inhibitors 2.5.1 HIV fusion inhibitors 2.5.2 CCR5 inhibitors 2.6 Triumph of modern medicine Chapter 3. Hepatitis Drugs 3.1 Hepatitis A virus 3.1.1 Discovery of hepatitis A virus 3.1.2 Hepatitis A vaccines 3.2 Hepatitis B virus 3.2.1 Discovery of hepatitis B virus 3.2.2 Hepatitis B vaccines 3.2.3 Hepatitis B drugs 3.3 Hepatitis C virus 3.3.1 Discovery of Hepatitis C virus 3.3.2 Hepatitis C virus NS3/4A protease inhibitors 3.3.3 Hepatitis C virus NS5A replication complex inhibitors 3.3.4 Hepatitis C virus NS5B polymerase inhibitors 3.4 Triumph of modern medicines Chapter 4. Influenza: A Perennial Killer 4.1 Influenza, a perennial killer 4.2 A virus that changed the world: the 1918 Spanish flu pandemic 4.3 Discovery of the influenza virus 4.4 Influenza vaccines 4.4.1 History of vaccination 4.4.2 History of influenza vaccines 4.4.3 Influenza vaccines today 4.5 Influenza drugs 4.5.1 M2 inhibitors 4.5.2 Influenza virus neuraminidase inhibitors 4.5.3 Cap-dependent endonuclease https://en.wikipedia.org/wiki/Ribonuclease inhibitor Chapter 5. Coronaviruses 5.1 Coronavirus Drugs 5.1.1. SARS 5.1.2. MARS 5.1.3. SARS-CoV-2 5.2 COVID-19 Vaccines 5.2.1. Pfizer/Biotech's mRNA vaccine 5.2.2. Johnson & Johnson's viral vector vaccine 5.3 COVID-19 Drugs 5.3.1. Remdesivir (Veklury) 5.3.2. Dexamethasone Chapter 6. Closing Remarks Bibliography Chemical Structures of Antiviral Drugs

Read more less

Book SynopsisEMBARK Psychedelic Therapy for Depression: A New Approach for the Whole Person represents a critical step forward in the field of psychedelic therapy. The book is a comprehensive guide for clinicians, offering a groundbreaking therapeutic framework for administering psychedelic medicines in treating depression.The approach is gaining traction with 4,000 people registered for the EMBARK foundational training. Developed in response to identified gaps in existing models of psychedelic therapy, the EMBARK model addresses the need for an ethical and inclusive approach. It bridges gaps from previous psychedelic therapies, such as lack of attentiveness to the body and rigorous ethical practice. The EMBARK approach has a growing evidence-base: in a recent psychedelic clinical trial, 79% of participants schieved full remission from depression three weeks after treatment. Benefit persisted with 75% of participants in remission at the four-month follow upEMBARK offers a transdiagnostic and trans-drug approach adaptable to various indications and psychedelic medicines. It''s built on four Cornerstones of Care: Trauma-Informed Care, Culturally Competent Care, Ethically Rigorous Care, and Collective Care, reflecting the belief that efficacious treatment is ethical treatment. The EMBARK acronym represents six Clinical Domains that commonly emerge for people in psychedelic experiences: Existential-Spiritual, Mindfulness, Body Aware, Affective-Cognitive, Relational, and Keeping Momentum.The book provides practical instructions and suggested agendas for therapists, and offers a flexible, participant-centric approach to integration, focusing on the clinical domains that emerged for the participant. It also links theory to practice for the treatment of depression, drawing from twelve proposed psychological mechanisms of therapeutic change in psychedelic therapy, and provides a comprehensive guide to treatment factors. EMBARK psychedelic therapy is open-sourced to the clinical community for development and adaptation to other psychedelic medicines, diverse populations, and to inform the development of psychedelic practitioner trainings, making it an essential resource for those interested in the field of psychedelic therapy.

Read more less

Book SynopsisIn The History of MDMA, Torsten Passie aims to explore a deeper and more differentiated understanding of MDMA and its history. He has conducted personal interviews with most of the people significant in the history of MDMA and provides a lot of new material to present the first comprehensive overview of the history of MDMA in Europe and the U.S.Trade ReviewThis is a necessary study that disentangles the complicated aspects of the recent and still ongoing history of MDMA. It is clearly presented, covering all aspects inside and out [...]. This book should certainly be in medical schools, public health departments, history of science and medicine units, and hopefully also among lawmakers. * Alain Touwaide, PhD (at the Ronin Institute) *Table of ContentsPreface Introduction 1: The Early History 2: MDMA and the Military 3: Rise of a Recreational Drug 4: The Research of Alexander T. Shulgin 5: Early Use in Psychotherapy 6: The Popularization 7: The Scheduling 8: Pioneers and Studies 9: MDMA as a Dance Drug 10: The British Rave Boom 11: The Toxicity Debate 12: Recent Developments Appendix: History of the Names of MDMA

Read more less

Book SynopsisA nuanced portrait of a daring subculture that continues to push the limits of religious experience and intellectual possibility.Trade ReviewAltered States genuinely moves forward in laying a path for new, insightful, and valuable information on the American Buddhism that is developing in our global society. Douglas Osto's groundbreaking research will be appreciated by scholars, and his accessible style will be enjoyed by nonacademic readers. -- Charles Prebish, author of Luminous Passage: The Practice and Study of Buddhism in America Altered States deftly guides us through the neglected territory of psychedelic Buddhism. This is a fascinating story, full of vivid characters and supported by solid research. Still, I believe it makes a greater contribution by situating these practices and persons within the larger contexts of tantra, of American religion, and of cutting-edge neuropsychology and consciousness studies. The result is-to use le mot juste-mind blowing. -- Franz Metcalf, author of What Would Buddha Do?: 101 Answers to Life's Daily Dilemmas "[Altered States] mixes statistics and surveys, historical overview, personal experience, and ethnographic texture to uncover the intertwining history of two fast-growing movements in American spirituality... This overview will appeal to anyone interested in Buddhism, psychedelic possibilities, and understanding how both are forging a controversial new American religious experience. Publishers Weekly Provocative... The book is worth buying, reading, and quoting. PsycCritiquesTable of ContentsPreface Acknowledgments Introduction 1. Buddhism and the Psychedelic Connection 2. The Psychedelic Revolution 3. The Buddhist Revolution 4. Opening the Door: Psychedelics as a Gateway to Buddhist Practice 5. Closing the Door: The Fifth Precept and Graduating from Psychedelics 6. Keeping the Door Open: Psychedelics as an Adjunct to Buddhist Practice 7. Are Psychedelics "the True Dharma"?: Debates, Presuppositions, and Philosophical Issues Conclusions Postscript Notes Bibliography Index

Read more less

Book SynopsisTrade Review"This is an excellent resource. Chapters are clearly and efficiently written. With the move towards digital communication, access to the website version is very helpful." -Aaron Plattner, MD (Pine Rest Christian Mental Health Services) Doody's Score: 96 - 4 Stars!

Read more less

Book SynopsisPsychotropic drugs are used widely with the elderly, but formal knowledge and training are often poor. With a focus on geriatric considerations such as medical issues, disabilities and nursing-home situations, this handbook gives clinicians the facts they need to work with elderly clients.

Read more less

Book SynopsisCognitive Behavioral Therapy for Preventing Suicide Attempts is a practical, clinician-friendly, how-to guide that demonstrates how to effectively reduce the risk for suicide attempts in any setting. Trade Review"I learned a lot from reading this book. From emergency and inpatient settings to the military environment and beyond, Cognitive-Behavioral Therapy for Preventing Suicide Attempts gets down to the nitty gritty of working with people at significant risk of suicide. Firmly based in research, yet clinically rich, this book is a veritable Swiss Army knife of suicide prevention manuals. Essential reading for all mental health clinicians, regardless of therapeutic orientation." Thomas E. Ellis, PsyD, ABPP, director of psychology at the Menninger Clinic and professor of psychiatry and behavioral science at the Baylor College of Medicine"This landmark text is a superb contribution to clinical suicidology. Expertly edited, it includes chapters from an all-star lineup of the field’s top authorities on CBT for suicide and deftly covers a range of views on cognitive-behavioral treatments for suicidal risk across a variety of clinical settings. It’s an indispensable book on a proven approach for effectively treating suicidal risk, and it will undoubtedly help save lives." David A. Jobes, PhD, ABPP, professor of psychology and associate director of clinical training at the Catholic University of America, Washington DC"There is an unfortunate shortage of evidence-based interventions and guidance for those working with patients at risk of suicide. This book is both practical and extremely helpful. Dr. Bryan and his colleagues are to be commended for meeting the needs of clinicians in multiple treatment settings." Timothy W. Lineberry, MD, former board chair of the American Association of Suicidology and former medical director of the Mayo Clinic Psychiatric HospitalTable of ContentsIntroduction Craig J. Bryan Section I: Understanding Suicide 1. The Problem of Suicide Michael D. Anestis and Lauren R. Khazem 2. The Language of Suicide Bridget B. Matarazzo, Beeta Y. Homaifar, Samantha A. Farro, and Lisa A. Brenner 3. What We Know and Don’t Know About Treating Suicide Risk Ann Marie Hernandez Section II: The Cognitive Behavioral Model of Suicide 4. A Cognitive Behavioral Model of Suicide Risk Tracy A. Clemans 5. Cognitive Therapy for Suicide Prevention: An Illustrative Case Example Kelly L. Green and Gregory K. Brown Section III: Suicide Prevention in Different Settings 6. Treating Risk for Self-Directed Violence in Inpatient Settings Marjan Ghahramanlou-Holloway, Laura L. Neely, and Jennifer Tucker 7. Preventing Suicide Attempts in Military Settings Craig J. Bryan and M. David Rudd 8. Treating Suicide Risk in Emergency Departments Emily Biggs, Cemile Ceren Sonmez, and Barbara Stanley 9. Treating Self-Directed Violence in Primary-Care Settings Craig J. Bryan and Peter C. Britton Section IV: Special Issues Special Issues with Treating Suicidal Patients Craig J. Bryan

Read more less

Book SynopsisCombining medication and cognitive behavioral therapy (CBT) can be challenging but can also enhance patient care. This book reviews the existing literature about the neurobiological and clinical basis in combining CBT and medication for non-psychiatrist mental health clinicians.Trade Review"Perhaps the most valuable aspect of the book, though, are the guidelines for collaborative care and the professional socialization provided as to how important it is for providers to establish trust and communicate well. There is a good discussion of how to set up collaborative relationships and of the kinds of information and policies that providers should share." (PsycCRITIQUES, Volume 56, Issue 51)Table of ContentsPreface v 1 Medication Versus CBT: How Did That Happen? 1 2 Neurobiological Evidence and Combined Treatment 9 3 Dual Responsibility Treatment: Principles That Facilitate Collaborative Patient Care 19 4 Combining CBT Interventions and Medication to Enhance Medication Adherence 35 5 Combined Treatment for Major Depression 55 6 Combined Treatment for Bipolar Disorder 81 7 Combined Treatment for Anxiety Disorders 103 8 Combined Treatment for Eating Disorders 119 9 Combined Treatment for Schizophrenia 139 10 Combined Treatment for Borderline Personality Disorder 159 11 Combined Treatment in Pregnancy 181 12 Combined Treatment for Substance Abuse and Dependence—written with Samson Gurmu, M.D. 193 References 209 Author Index 235 Subject Index 243

Read more less

Book Synopsis"Dr. Paris has written an honest, balanced presentation of the waysin which psychiatric drugs are evaluated and prescribed. Hehighlights the complexity of the task, the limits of what is knownand the mixed picture that research often produces.Trade Review“The Use and Misuse of Psychiatric Drugs deserves a place in every health sciences library.” (Metapsychology Online Reviews, 8 January 2013) "In the book’s foreword, Tyrer describes this book as a ‘‘well balanced sober account of a serious issue that affects almost all of us in one way or another’’ and I would agree with that. The book is well written, easy to read, and makes good bedtime reading despite the serious nature of its topic. Epidemiologists will find it useful as background to the use of these medications, even if observational studies were neglected. ... Paris is not afraid to tackle controversial topics and make forceful statements about issues where improvement is needed. I highly recommend this book to anyone who would like to know more about this topic." (Annals of Epidemiology, 2012)Table of ContentsForeword. Introduction. Part I OVERVIEW. 1 The History of Psychopharmacology. 2 The Science of Psychopharmacology. 3 The Pharmaceutical Industry. Part II DRUGS IN PRACTICE. 4 Antipsychotics: For Better or For Worse. 5 Mood Stabilizers and Mood Instability. 6 Antidepressants. 7 Prescribing for Children and Adolescents. 8 Polypharmacy. Part III PERSPECTIVES. 9 Alternatives to Drugs. 10 Medicalizing Distress. 11 The Future of Psychopharmacology. References. Index.

Read more less

Book SynopsisThis book fulfils an urgent need for an updated text on pediatric psychopharmacology. It takes a unique approach in discussing recent findings within the context of current issues, including economic and political ones. The book covers the emerging question of treating children who do not yet meet diagnostic criteria for psychosis, e.g, schizophrenia or bipolar disorder, but who are deemed to be at high risk. This is an active area of debate: such children are being treated in certain centers, while others reject this completely. The book addresses the antidepressant controversy, the placebo response and unique strategies for delineating this, and ways to optimize the differential between active medication and placebo. It reviews the impact of recent American Heart Association guidelines for monitoring children on stimulants and other psychotropics. It adheres closely to DSM-IV diagnostic criteria throughout. The book describes the use of newly approved drugs such as Lexapro for treatiTrade Review “Pharmacotherapy of Child and Adolescent Psychiatric Disorders is a book to have available on your desk, not just in your library. It provides ready access to the wealth of practical information and insight for the range of health and mental health professionals. It is highly recommended for trainees and anyone who is prescribing psychotropic medications to the pediatric population and young adults.” (Journal of Clinical Psychiatry, 7 July 2012) Table of ContentsList of Contributors, xv Foreword, xix Chapter 1 Historical Perspectives on Child and Adolescent Psychopharmacology, 1 Samuel Gershon References, 4 Chapter 2 Pharmacoepidemiology of Psychotropic Medications in Youth, 7 Daniel J. Safer & Julie Magno Zito Introduction, 7 Prevalence and trends for medications prescribed for ADHD, 8 Nonstimulant medications for ADHD, 11 Antidepressant medication, 11 Antipsychotic medication, 13 Alpha-agonists, 14 Anticonvulsant "mood stabilizers", 15 Concomitant psychotropic medication, 15 Preschool psychotropic medication use, 17 International patterns of psychotropic medication for youth, 17 Conclusion, 18 References, 18 Chapter 3 Off-Label Prescribing of Drugs in Child and Adolescent Psychiatry, 25 C. Lindsay DeVane Introduction, 25 Extent of off-label prescribing, 27 Need for psychoactive drug treatments for children and adolescents, 31 Legislation supporting pediatric drug development, 33 Recommendations to follow when considering off-label prescribing, 35 References, 36 Chapter 4 The Use of Generic Drugs in Pediatric Psychopharmacology, 39 Richard I. Shader & Christopher-Paul Milne What is a generic drug?, 39 Why are we discussing generic drugs?, 39 Basic requirements for generic drugs, 40 The status of regulations regarding generic drugs and children, 41 Abbreviated new drug application (ANDA) requirements, 42 Pediatric assessments of adult drugs (history up to current status), 43 Best Pharmaceuticals for Children Act, 44 Pediatric Research Equity Act, 45 Intersection of requirements for generics and pediatric assessment, 46 Future directions, 48 Concluding thoughts, 49 References, 49 Chapter 5 Psychoactive Drug Use in Children: Basic Concepts in Clinical Pharmacology, 51 David J. Edwards Introduction, 51 Basic concepts in pharmacokinetics, 52 Dosing considerations for psychoactive drugs in children, 55 Summary, 60 References, 60 Chapter 6 Psychostimulants, 65 Steven R. Pliszka Introduction, 65 Epidemiology of stimulant use, 66 Structure and biochemical mechanism of action, 66 Neuroimaging studies of stimulant effects, 67 Studies of short-term efficacy, 72 Studies of long-term efficacy, 76 Clinical use, 79 Common side-effects, 84 Cardiovascular safety issues, 86 Growth suppression, 88 Substance use and diversion, 88 Comparison with nonstimulant treatment, 89 Treatment of comorbidity, 92 Pharmacogenetics, 93 Conclusions, 94 References, 94 Chapter 7 Tricyclic Antidepressants and Monoamine Oxidase Inhibitors for the Treatment of Child and Adolescent Psychiatric Disorders, 105 Charlotte M. Heleniak, Tejal Kaur, Kareem D. Ghalib & Moira A. Rynn Tricyclic antidepressants (TCAs), 105 Drug interactions, contraindications, 116 Monoamine oxidase inhibitors (MAOIs), 117 General summary, 122 References, 123 Chapter 8 Selective Serotonin Reuptake Inhibitors (SSRIs), 131 Dara Sakolsky & Boris Birmaher Pharmacokinetics, 131 Initiation and titration, 133 Indications and efficacy, 134 Adverse effects, 146 Withdrawal, 149 References, 149 Chapter 9 Novel (Atypical) Antidepressants, 155 Heidi R. Bruty, Graham J. Emslie & Paul Croarkin Novel (atypical) antidepressants, 155 General overview, 155 Bupropion, 157 Duloxetine, 162 Mirtazapine, 164 Trazodone, 166 Venlafaxine, 170 Desvenlafaxine, 173 Alternative treatments, 174 Summary, 175 References, 176 Chapter 10 Antipsychotic Agents, 181 Brieana M. Rowles, John L. Hertzer & Robert L. Findling Introduction, 181 Chemical properties, 182 Typical antipsychotics, 183 Atypical antipsychotics, 186 Ethical issues: treatment of at-risk populations, 212 Conclusions, 213 References, 213 Chapter 11 Lithium, 221 Garrett M. Sparks & David A. Axelson Introduction, 221 Pharmacology, 222 Potential mechanisms of action, 222 Evidence for the use of lithium in children and adolescents, 232 Dosing and drug monitoring, 239 Contraindications, precautions, and drug interactions, 242 Side-effects, 246 References, 250 Chapter 12 Anticonvulsants Used in Child and Adolescent Psychiatric Disorders, 261 Mani Pavuluri & Tushita Mayanil Introduction, 261 Divalproex sodium, 261 Carbamazepine, 271 Oxcarbazepine, 275 Lamotrigine, 279 Gabapentin, 284 Topiramate, 285 Conclusion, 288 References, 288 Chapter 13 Anxiolytics, 301 Barbara J. Coffey & Amanda L. Zwilling Chemical properties, 301 Indications, 305 Contraindications, 320 Adverse effects, 321 Overdose, 324 Abuse/dependence, 324 Drug interactions, 325 Available preparations and cost, 325 Initiation and maintenance of treatment, 325 Management of specific side-effects, 330 How to withdraw medication, 332 References, 332 Chapter 14 Adrenergic Agents in Child and Adolescent Psychiatry, 341 Lawrence David Scahill Clonidine and guanfacine, 341 Guanfacine, 349 Beta-blockers, 355 Acknowledgements, 361 References, 361 Chapter 15 Atypical Psychopharmacologic Strategies, 365 Jess Shatkin & Aron Janssen Opiate antagonists, 365 Memantine, 368 Riluzole, 369 Secretin, 371 Topiramate, 372 Herbal medications and dietary supplements, 373 Ginkgo (Ginkgo biloba), 375 Melatonin, 381 Omega-3 fatty acids, 383 St. John's wort (Hypericum perforatum), 384 Valerian (Valeriana officinalis), 387 Conclusion, 388 References, 389 Chapter 16 Psychopharmacology in Preschool Children, 399 Mini Tandon & Joan Luby Introduction, 399 Developmental considerations, 400 Rise in psychopharmacology use, 402 Psychotherapy before psychopharmacology, 403 When psychopharmacology may be considered as a first line: pragmatic considerations, 404 Psychopharmacology in preschool disorders: administration and monitoring, 404 Off-label prescribing: special considerations, 407 Use of psychotropics in specific disorders, 408 Summary, 415 References, 415 Chapter 17 Combination Pharmacotherapy for Psychiatric Disorders in Children and Adolescents, 421 Gagan Joshi & Anna M. Georgiopoulos Bipolar disorder, 422 Major depressive disorder, 429 Attention-deficit hyperactivity disorder, 431 Obsessive-compulsive disorder, 433 Tics and Tourette's syndrome, 434 Pervasive developmental disorders, 434 Conclusion, 434 References, 435 Index, 439

Read more less

Book SynopsisFROM PLACEBO TO PANACEA With the latest generation of psychoactive drugs, has pharmacologyat last triumphed over mental illness? A close look at worldscientific literature would suggest otherwise. The sobering truthis that many claims about the efficacy of drug therapies foreverything from depression to schizophrenia have been exaggerated.What, then, accounts for the inflated confidence clinicians and thelay public alike often have in the new generation of wonderdrugs? Find out in From Placebo to Panacea. From Placebo to Panacea is not an indictment of drug therapy.Rather, it is a reasoned analysis of the efficacy of psychoactivedrugs as compared to other forms of treatment--backed by hardempirical data. Above all, it is meant to function as a therapist''sand patient''s guide to making more informed decisions whenconsidering treatment options. The book begins with an in-depth discussion of salient problemswith standard methods of measuring the usefulness of pTable of ContentsPartial table of contents: CONCEPTUAL ISSUES. The Curse of the Placebo: Fanciful Pursuit of a Pure BiologicalTherapy (S. Fisher & R. Greenberg). Treatment Implications of Psychiatric Comorbidity (M.Greenberg). Costly Compromises: A Critique of the Diagnostic and StatisticalManual of Mental Disorders (R. Carson). EFFICACIES OF PSYCHOACTIVE DRUGS FOR ADULTS. A Critique of the Use of Neuroleptic Drugs in Psychiatry (D.Cohen). A Focused Empirical Analysis of Treatments for Panic and Anxiety(W. Danton & D. Antonuccio). EFFICACIES OF PSYCHOACTIVE DRUGS FOR CHILDREN. Are We Justified in Treating Children with PsychoactiveDrugs? (R. Fisher & S. Fisher). Stimulant Pharmacotherapy for Attention- Deficit/HyperactivityDisorders: An Analysis of Progress, Problems, and Prospects (C.Whalen & B. Henker). OVERVIEW. What Are We to Conclude About Psychoactive Drugs?: Scanning theMajor Findings (S. Fisher & R. Greenberg). Indexes.

Read more less

Book SynopsisThis book focuses on psychopharmacological treatments of DSM-IV-TRACA' categories for which there are known treatments, including ADHD, dementia, substance use, schizophrenia, and bi-polar disorders, among others. It contains all of the necessary elements for clinicians to develop individualized formal treatment plans for relational problems.Table of ContentsIntroduction Adjustment Disorder with Depression or Anxiety Anger Management Antisocial Behavior Anxiety Attention Deficit/Hyperactivity Disorder (ADHD) - Adult Borderline Personality Chemical Dependence - Relapse Prevention Chemical Dependence - Withdrawal Chronic Fatigue Syndrome Chronic Pain Cognitive Deficits - Dementia Cognitive Deficits - Developmental Disorder Depression Dissociation Eating Disorder Female Sexual Dysfunction Impulse Control Disorder Male Sexual Dysfunction Mania / Hypomania Medical Issues - Delirium Obsessive-Compulsive Disorder (OCD) Phobia-Panic/Agoraphobia Posttraumatic Stress Disorder (PTSD) Psychoticism Sleep Disorder Social Discomfort Somatization Suicidal Ideation Commonly Used Psychiatric Medications Index of DSM-IV-TR Codes Associated with Presenting Problems

Read more less

Book SynopsisRecent years have seen major advances in the understanding andtreatment of health anxiety and hypochondriasis, particulary inrelation to the cognitive behavioural approach to anxiety. Thisvolume brings together this knowledge of psychological andpharmacological treatments of health anxiety, and relates it to aconceptual framework which provides a basis for assessment,treatment and ongoing research. Asmundson, Taylor and Cox have assembled a group of world classscientists and practitioners for this book. The chapters provide awealth of information on the causes, assessment and treatment ofhealth anxiety related disorders. I believe that their book is themost significant contribution to date to our understanding ofhealth anxiety related disorders. Everyone working in the healthfield will find something of worth in this book. G. Ron Norton, Ph.D, Professor Emeritus, University of Winnipeg,CanadaTrade Review"...This book will give you the current status in the field from aninternational perspective..." (Int Jnl of Adolescent MedicalHealth, Vol.14, No.3, 2002) "...It is well structured, clearly written and provides anexcellent and comprehensive overview of the subject..."(British Journal of Clinical Psychology, September 2002)Table of ContentsAbout the Editors. List of Contributors. Foreword: Professor S. Rachman. Preface. Acknowledgments. PART I: CLINICAL FEATURES AND THEORETICAL PERSPECTIVES. 1. Health Anxiety: Classification and Clinical Features (Gordon J.G. Asmundson, Steven Taylor, Serperi Sevgur, and Brian J.Cox). 2. The Psychology of Physical Symptoms and Illness Behavior (ReneMartin, Katherine Lemos, and Howard Leventhal). 3. Making Sense of Hypochondriasis: A Cognitive Theory of HealthAnxiety (Paul M. Salkovskis and Hillary Warwick). 4. Personality Traits and Health Anxiety (Erin McClure and Scott O.Lilienfeld). PART II: ASSESSMENT AND TREATMENT. 5. Assessment of Health Anxiety (Sherry Stewart and Margo C.Watt). 6. Hypochondriasis: Boundaries and Comorbidities (Russell Noyes,Jr.). 7. Integrated Approach to Cognitive-Behavioral Therapy for IntenseIllness Worries (Patricia Furer, John R. Walker, and Mark H.Freeston). 8. Pharmacological Management of Hypochondriasis and RelatedDisorders (Murray W. Enns, Kevin Kjernisted, and MarkLander). 9. General and Cross-Cultural Considerations in a Medical Settingfor Patients Presenting with Medically Unexplained Symptoms (JavierI. Escobar, Lesley A. Allen, Constanza Hoyos Nervi, and Michael A.Gara). 10. Hypochondriasis and Health Anxiety in the Elderly (Allison G.Snyder and Melinda A. Stanley). PART III: RELATED CONDITIONS. 11. Heart-focussed Anxiety in Medical and Anxiety-relatedPsychological Conditions (Georg H. Eifert, Michael J. Zvolensky,and Carl W. Lejuez). 12. Hypochondriasis and Health Anxiety among Pain Patients (HeatherD. Hadjistavropoulos, Katherine M. B. Owens, ThomasHadjistavropoulos, and Gordon J. G. Asmundson). 13. Psychotic Disorders with Hypochondriacal Features: Delusions ofthe Soma (David Kingdon, Shanaya Rathod, and DouglasTurkington). 14. Death Anxiety (Robert J. Kastenbaum). PART IV: CONCLUSIONS AND FUTURE DIRECTIONS. 15. Future Directions and Challenges in Assessment, Treatment, andInvestigation (Gordon J. G. Asmundson, Steven Taylor, Kristi D.Wright, and Brian J. Cox). Author Index. Subject Index.

Read more less

Book SynopsisTreatment with drugs is fundamental to modern therapy of psychiatric disorders. The number of disorders responsive to drug treatment is increasing, reflecting the extensive synthesis of novel compounds and the greater understanding of the aetiology of the disorders. This third edition provides new and updated material, including an additional chapter on clinical trials and their importance in assessing the efficacy and safety of psychotropic drugs. As molecular biology and imaging techniques are of increasing importance to basic and clinical neuroscience, these areas have also been extended to illustrate their relevance to our understanding of psychopharmacology. This book is essential reading for undergraduates in pharmacology and the neurosciences, postgraduate neuropharmacologists, psychiatrists in training and in practice and medical researchers. Reviews of the Second Edition this text is eminently readable, well researched, and probably the best of Trade Review“…one of the best in the area of psychopharmacology…well written, concise and easy to understand with clear and informative figures and tables…highly recommended. (Human Psychopharmacology, Vol.20, No.1, January 2005)Table of ContentsPreface to Third Edition. Preface to Second Edition. Preface to First Edition. Introduction. 1. Functional Neuroanatomy of the Brain. 2. Basic Aspects of Neurotransmitter Function. 3. Pharmacokinetic Aspects of Psychopharmacology. 4. Clinical Trials and Their Importance in Assessing the Efficacy and Safety of Psychotropic Drugs. 5. Molecular Genetics and Psychopharmacology. 6. Psychotropic Drugs that Modify the Serotonergic Systems. 7. Drug Treatment of Depression. 8. Drug Treatment of Mania. 9. Anxiolytics and the Treatment of Anxiety Disorders. 10. Drug Treatment of Insomnia. 11. Drug Treatment of Schizophrenia and the Psychoses. 12. Drug Treatment of the Epilepsies. 13. Drug Treatment of Parkinson's Disease. 14. Alzheimer's Disease and Stroke: Possible Biochemical Causes and Treatment Strategies. 15. Psychopharmacology of Drugs of Abuse. 16. Paediatric Psychopharmacology. 17. Geriatric Psychopharmacology. 18. The Inter-relationship Between Psychopharmacology and Psychoneuroimmunology. 19. Endocoids and Their Importance in Psychopharmacology. Appendix 1: Some Important Psychotropic Drug Interactions. Appendix 2: Glossary of Some Common Terms Used in Psychopharmacology. Appendix 3: Generic and Proprietary Names of Some Common Psychotropic Drugs. Appendix 4: Key References for Further Reading. Index.

Read more less

Book SynopsisThe Stahl''s Illustrated books are a series of pocket-sized, mid-priced, themed volumes. They distil theoretical information from the Stahl''s Essential Psychopharmacology volume and combine this with practical data from The Prescriber''s Guide. They are illustration heavy and designed to encourage speedy learning of both concepts and applications. The visual learner will find that these books make the concepts easier to master, and the non-visual learner will appreciate the clear, shortened text on complex psychopharmacological concepts. This volume covers the latest developments in our understanding of post-traumatic stress disorder and anxiety. As well as covering the full range of management options, there is a specific focus on the implications for military populations. The Stahl''s Illustrated series appeals to the widest possible audience of mental health professionals, and not just those with expertise in psychopharmacology.Table of Contents1. Neurobiology of stress and anxiety; 2. Post-traumatic stress disorder (PTSD); 3. Neurotransmitter systems as pharmacological targets for PTSD; 4. First-line medications for PTSD; 5. Second-line, adjunct, and investigational medications for PTSD; 6. Cognitive behavioral therapy (CBT) for PTSD; 7. Caring for patients with PTSD; 8. Unique considerations for the military population; Summary.

Read more less

Book SynopsisNow in paperback. In the tradition of Lori Gottlieb and Henry Marsh, a distinguished psychiatrist examines his own practice. Alastair Santhouse knew something was wrong the night he was on call during his medical training and got the news that a woman on the way to the ER had died in the ambulance. That meant he could go back to sleep! But he couldn't. He was overtaken with the sense that his joyful reaction was terrible failure. That night began his long journey away from the ER and into psychiatry. Head First chronicles Santhouse's many years treating patients and his exploration of the ways in which our minds exert a huge and underappreciated influence over our health. They shape our responses to symptoms that we develop, dictate the treatments we receive, and influence whether they work. They even influence whether we develop symptoms at all. Written with brutal honesty, deep compassion, and a wry sense of humor, Head First examines difficult cases that illuminate some of our most puzzling and controversial medical issues--from the tragedy of suicide, to the stigma surrounding obesity, to the mysteries of self-induced illness. Ultimately he finds that our medical model has failed us by promoting specialization and overlooking perhaps the single most important component of our health: our state of mind. 

Read more less

Book SynopsisTable of ContentsSection 1 Management of the psychoses 2 The antipsychotics 3 Antipsychotic side effects and their management References Section 2 Management of depression 4 The antidepressants 5 Side effects of antidepressants References Section 3 Management of bipolar disorders 6 Management of acute bipolar disorder 7 Mood-stabilisers References Section 4 Stimulants & Drugs for children 8 Stimulants & Drugs for children References Section 5 Management of anxiety 8 The anxiety disorders 10 Benzodiazepine anxiolytics 11 Anxiolysis and the serotonin system 12 Beta-blockers and anxiety References Section 6 Management of sleep disorders and insomnia 13 Sleep disorders and insomnia 14 Non-pharmacological management of insomnia 15 Hypnotics 16 Sedatives References Section 7 Management of cognitive impairment 17 Cognitive enhancement and the dementias 18 Cognitive enhancement and neuroprotection References Section 8 Management of sexual difficulties 19 The range of sexual difficulties 20 Effects of drugs on aspects of sexual functioning Appendix 20.1 Male sexual functioning questionnaire Appendix 20.2 Female sexual functioning questionnaire References Section 9 Management of dependence and withdrawal 21 Dependence & Withdrawal 22 Dependence & Craving 23 Dependence & Protracted Withdrawal References Section 10 Consent, abuse and liability 24 Consent 25 Pharmacological abuse References Section 11 The marketing of tranquillity 26 The ethical industry 27 Evidence-biased care 28 Marketing & Risk 29 From healthcare to pharmageddon

Read more less

Book Synopsis

Read more less

Book SynopsisThe fourth volume in Stahl's Case Studies series describing the approach, diagnosis, and treatment of children and adolescents with psychiatric disorders. Demonstrating core principles that allow clinicians to individualize treatment and engage families, creating the best outcomes. Essential reading for mental health professionals and students.Trade Review'This collection of case studies is the most comprehensive and clinically relevant that I have ever read. As a practicing Child and Adolescent Psychiatrist, I have come face to face with many of the same clinical presentations and found Dr Strawn's review of the management thoughtful and integrative. It provides a unique framework for approaching these difficult interactions and offers a glimpse into how to combine science with the art of psychopharmacology when the evidence base is lacking. The emphasis on unique child and adolescent disorders, family dynamics and developmental pharmacology, outlines not just what the patient may need but also why. This is a must have for any Child and Adolescent Psychiatrist's library. I will certainly use it when teaching my residents and fellows and in my own practice as well.' Nicole M. Ballinger, DO, MPH, FAPA, Medical Staff President/Director, Child and Adolescent Psychiatry, Aurora Psychiatric Hospital, Wauwatosa, WI'Drs. Strawn and Stahl have really done it! The case-based teaching format and dozens of easy-to-read graphs and illustrations, walks clinicians of all levels through the complex world of pediatric psychopharmacology. Using easy-to-follow color-coded backgrounds and icons, the cases illustrate the evolution of each patient's treatment, the interplay of science and clinical wisdom, and the common pitfalls in the practice of pediatric psychopharmacology. In this era of rapidly advancing knowledge, this book provides a foundation rooted in the latest clinical pharmacology literature; it is a must-read for anyone practicing pediatric psychopharmacology.' John T. Walkup, M.D., Margaret C. Osterman Professor of Psychiatry Chair, Pritzker Department of Psychiatry and Behavioral Health; Ann and Robert H. Lurie Children's Hospital of Chicago; President-Elect, American Academy of Child & Adolescent Psychiatry'This book walks with you hand-in-hand as it describes common clinical challenges encountered while psychiatrically treating a child or adolescent. This is a must-have for novice and experienced clinicians alike, to provide clear guidance on ways to address a wide range of clinical scenarios affecting youth. In today's complex and burdened healthcare environment, this essential psychopharmacology for child and adolescent psychiatry gives the busiest clinicians readily available tools to navigate complex scenarios with clear, sequential, and logical guidance. The clinical pearls are written in pragmatically and with adult learning principles in mind. Thank you, Drs Stahl and Strawn, for capitulating the wisdom of our field in such an accessible and engaging way.' Manpreet Kaur Singh, M.D., M.S., Associate Professor of Psychiatry and Behavioral Sciences, Stanford University, StanfordTable of ContentsIntroduction; List of icons; Abbreviations; 1. The case: the salutatorian who couldn't speak: Selective Serotonin Reuptake Inhibitor (SSRI)-refractory anxiety in an adolescent; 2. The case: from anxious to activated: Selective Serotonin Reuptake Inhibitor (SSRI)-related activation; 3. The case: the girl who couldn't sleep: Posttraumatic Stress Disorder (PTSD) in a young girl; 4. The case: depressed and still depressed: Major Depressive Disorder (MDD) in an adolescent; 5. The case: a 13-year-old adolescent who feels 'amazing': Selective Serotonin Reuptake Inhibitor (SSRI)-induced mania in an adolescent; 6. The case: counting on a cure: Obsessive–Compulsive Disorder (OCD) in an adolescent; 7. The case: struggles in the second grade: Attention-Deficit Hyperactivity Disorder (ADHD) in a child; 8. The case: from prodrome to psychosis: early-onset schizophrenia; 9. The case: too much, too little, or just right? lithium dosing in an adolescent; 10. The case: tic, tic, tic: motor and vocal tics in a boy; 11. The case: how slow can you go? Selective Serotonin Reuptake Inhibitor (SSRI) withdrawal and discontinuation in an adolescent; 12. The case: the adolescent who doesn't eat: anorexia nervosa in an adolescent; 13. The case: high or higher antidepressant concentrations? cannabis-related drug interactions in an adolescent; 14. The case: the boy whose bed was always wet: nocturnal enuresis in a child; 15. The case: counting sheep and counting treatment trials: insomnia disorder in an adolescent; 16. The case: Second-Generation Antipsychotics (SGAs), side effects, and the autism spectrum: SGA-related side effects in a boy with Autism Spectrum Disorder (ASD); 17. The case: the 'standard treatment' is earning a 'D': treatment-resistant schizophrenia; 18. The case: symptoms, side effects, or both? Selective Serotonin Reuptake Inhibitor (SSRI) tolerability and physical symptoms in an anxious adolescent; Index.

Read more less

Book Synopsis

Read more less

Book SynopsisThis pocket-sized volume in the Stahl's Illustrated series combines theoretical information from Stahl's Essential Psychopharmacology with practical data from The Prescriber's Guide. This highly-illustrated guide presents the underlying neurobiology, genetic predisposition and management of aggressive behaviours in patients with psychiatric disorders.Table of ContentsPreface; CME information; Objectives; Introduction; 1. Which individuals will become violent or aggressive?; 2. Neurobiology and genetics of violence and aggression; 3. Treatment of violence and aggression; Summary; References; Index; CME: posttest and certificate.

Read more less